home / openregs

documents

Regulatory documents from Regulations.gov including rules, proposed rules, notices, and supporting materials.

Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API

19 rows where docket_id = "FDA-2006-N-0304" and posted_year = 2008 sorted by posted_date descending

✎ View and edit SQL

This data as json, CSV (advanced)

Suggested facets: subtype, posted_date, posted_month, comment_start_date, last_modified, posted_date (date), comment_start_date (date), last_modified (date)

document_type 2

  • Supporting & Related Material 13
  • Other 6

posted_year 1

  • 2008 · 19 ✖

agency_id 1

  • FDA 19
id agency_id docket_id title document_type subtype posted_date ▲ posted_year posted_month comment_start_date comment_end_date last_modified fr_doc_num open_for_comment withdrawn object_id
FDA-2006-N-0304-0028 FDA Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 Background Information - American Lung Association, Trends in Asthma Morbidity and Mortality, Epidemiology & Statistics Unit, Research and Program Services, July 2006. Supporting & Related Material BKG-Background Material 2008-12-08T05:00:00Z 2008 12     2008-12-08T18:26:08Z   0 0 09000064804593a8
FDA-2006-N-0304-0024 FDA Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 Background Information - National Heart, Lung, and Blood Institute, Expert Panel Report: Update on Selected Topics 2002: Guidelines for the Diagnosis and Management of Asthma, NIH publication No. 02-5074, June 2003 [Article continues in FDA-2006-N-0304-0025] Supporting & Related Material BKG-Background Material 2008-12-08T05:00:00Z 2008 12     2008-12-08T18:36:51Z   0 0 090000648045939c
FDA-2006-N-0304-0016 FDA Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 Background Information - Reference: Analysis completed by FDA based on information provided by IMS Health, IMS National Sales Perspective (TM), 2005, extracted March 2006. These data are available for purchase from IMS Health. Please send all inquiries to: IMS Health, Attn: Brian Palumbo, Account Manager, 660 West Germantown Pike, Plymouth Meeting, PA 19462 Supporting & Related Material BKG-Background Material 2008-12-08T05:00:00Z 2008 12     2008-12-08T18:25:54Z   0 0 0900006480459369
FDA-2006-N-0304-0020 FDA Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 Background Information - Reference: "Surveillance for Asthma — United States, 1980–1999 -- Malaria Surveillance — United States, 1999," MMWR Morbidity andMortality Weekly Report, 2002 Supporting & Related Material BKG-Background Material 2008-12-08T05:00:00Z 2008 12     2008-12-08T18:25:59Z   0 0 0900006480459377
FDA-2006-N-0304-0023 FDA Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 Background Information - References Supporting & Related Material BKG-Background Material 2008-12-08T05:00:00Z 2008 12     2008-12-08T18:26:02Z   0 0 0900006480459387
FDA-2006-N-0304-0022 FDA Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 Background Information - National Heart, Lung, and Blood Institute, Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma, NIH publication No. 97-4051, July 1997 - Continued [Article begins in FDA-2006-N-0304-0027] Supporting & Related Material BKG-Background Material 2008-12-08T05:00:00Z 2008 12     2008-12-08T18:35:31Z   0 0 0900006480459385
FDA-2006-N-0304-0027 FDA Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 Background Information - National Heart, Lung, and Blood Institute, Expert Panel Report 2: Guidelines for the Diagnosis and Management of Asthma, NIH publication No. 97-4051, July 1997 (continued in FDA-2006-N-0304-0022) Supporting & Related Material BKG-Background Material 2008-12-08T05:00:00Z 2008 12     2008-12-08T18:33:28Z   0 0 09000064804593a5
FDA-2006-N-0304-0026 FDA Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 Background Information - United Nations Environmental Programme, Production and Consumption of Ozone-Depleting Substances: 1986-2004, 2005 Supporting & Related Material BKG-Background Material 2008-12-08T05:00:00Z 2008 12     2008-12-08T18:26:06Z   0 0 09000064804593a3
FDA-2006-N-0304-0025 FDA Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 Background Information - National Heart, Lung, and Blood Institute, Expert Panel Report: Update on Selected Topics 2002: Guidelines for the Diagnosis and Management of Asthma, NIH publication No. 02-5074, June 2003 - continued Supporting & Related Material BKG-Background Material 2008-12-08T05:00:00Z 2008 12     2008-12-08T18:26:05Z   0 0 090000648045939f
FDA-2006-N-0304-0017 FDA Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 Background Information - Reference: Rozek, R.P., and E.R. Bishko, Economics Issues Raised in the FDA's Proposed Rule on Removingthe Essential-Use Designation for Albuterol MDIs, National Economic Research Associates, August 13, 2004 (FDA Docket No. 2003P-0029 C 25) Supporting & Related Material BKG-Background Material 2008-12-08T05:00:00Z 2008 12     2008-12-08T18:25:55Z   0 0 090000648045936a
FDA-2006-N-0304-0019 FDA Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 Background Information - Reference: U.S. Environmental Protection Agency, The Benefits and Costs of the Clean nAir Act: 1990-2010. (http://www.epa.gov/air/sect812/copy99.html) (November 1999). Supporting & Related Material BKG-Background Material 2008-12-08T05:00:00Z 2008 12     2008-12-08T18:25:57Z   0 0 0900006480459373
FDA-2006-N-0304-0021 FDA Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 Background Information - Reference: DeNavas-Walt, C., B.D. Proctor, and C.H. Lee, U.S. Census Bureau, Current Population Reports, P60-229, Income, Poverty, and Health Insurance Coverage in the United States: 2004, p. 18, 2005 Supporting & Related Material BKG-Background Material 2008-12-08T05:00:00Z 2008 12     2008-12-08T18:26:00Z   0 0 0900006480459378
FDA-2006-N-0304-0018 FDA Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 Background Information - Reference: "Chronic Obstructive Pulmonary Disease Surveillance — United States, 1971–2000" MMWR Morbidity and Mortality Weekly Report, CDC Supporting & Related Material BKG-Background Material 2008-12-08T05:00:00Z 2008 12     2008-12-08T18:25:56Z   0 0 0900006480459371
FDA-2006-N-0304-0014 FDA Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 Graceway Pharmaceuticals, LLC (Graceway) - Addendum to Comment Other AMD-Amendment 2008-07-21T04:00:00Z 2008 7 2008-07-21T04:00:00Z   2008-12-09T19:09:49Z   0 0 0900006480650364
FDA-2006-N-0304-0015 FDA Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 Abbott - Withdrawal Other WDL-Withdrawal 2008-07-21T04:00:00Z 2008 7 2008-07-21T04:00:00Z   2013-07-27T22:18:53Z   0 0 0900006480680030
FDA-2006-N-0304-0012 FDA Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 Graceway Pharmaceuticals, LLC - Request for Extension of Comment Due Date Other EXT-Request for Extension Comment Due Date 2008-07-21T04:00:00Z 2008 7 2008-07-21T04:00:00Z   2013-07-27T20:44:31Z   0 0 09000064804593ad
FDA-2006-N-0304-0013 FDA Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 Graceway Pharmaceuticals - Request for Extension of Comment Due Date Other EXT-Request for Extension Comment Due Date 2008-07-21T04:00:00Z 2008 7 2008-07-21T04:00:00Z   2013-07-27T20:44:31Z   0 0 09000064804593bc
FDA-2006-N-0304-0009 FDA Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 University of Alabama at Birmingahm (UAB) - Letter Other LET-Letter 2008-06-02T04:00:00Z 2008 6 2008-06-02T04:00:00Z   2008-06-03T00:17:05Z   0 0 09000064804593b9
FDA-2006-N-0304-0010 FDA Use of Ozone-Depleting Substances; Removal of Essential-Use Designations FDA-2006-N-0304 Lisa Delaney Correspondence to the Center for Drug Evaluation and Research - Electronic Letter Other ELET-Electronic Letter 2008-06-02T04:00:00Z 2008 6 2008-06-02T04:00:00Z   2008-06-03T00:17:06Z   0 0 090000648045aaf8

Advanced export

JSON shape: default, array, newline-delimited, object

CSV options:

CREATE TABLE documents (
    id TEXT PRIMARY KEY,
    agency_id TEXT,
    docket_id TEXT REFERENCES dockets(id),
    title TEXT,
    document_type TEXT,
    subtype TEXT,
    posted_date TEXT,
    posted_year INTEGER,
    posted_month INTEGER,
    comment_start_date TEXT,
    comment_end_date TEXT,
    last_modified TEXT,
    fr_doc_num TEXT,
    open_for_comment INTEGER,
    withdrawn INTEGER,
    object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;
Powered by Datasette · Queries took 3731.82ms · Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API